JP2017524704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524704A5 JP2017524704A5 JP2017504421A JP2017504421A JP2017524704A5 JP 2017524704 A5 JP2017524704 A5 JP 2017524704A5 JP 2017504421 A JP2017504421 A JP 2017504421A JP 2017504421 A JP2017504421 A JP 2017504421A JP 2017524704 A5 JP2017524704 A5 JP 2017524704A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- substituted
- acceptable salt
- compound according
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 ethylene, propylene Chemical group 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 201000005569 Gout Diseases 0.000 claims description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000003566 oxetanyl group Chemical group 0.000 claims description 8
- 125000000466 oxiranyl group Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 229940116269 uric acid Drugs 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 201000001431 Hyperuricemia Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 102000005773 Xanthine dehydrogenase Human genes 0.000 claims description 4
- 108010091383 Xanthine dehydrogenase Proteins 0.000 claims description 4
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 206010007027 Calculus urinary Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000000913 Kidney Calculi Diseases 0.000 claims description 2
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims description 2
- 206010027439 Metal poisoning Diseases 0.000 claims description 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 2
- 229940122272 Oxidoreductase inhibitor Drugs 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 claims description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical group OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 2
- 229960003459 allopurinol Drugs 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 230000029142 excretion Effects 0.000 claims description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims description 2
- 229960005101 febuxostat Drugs 0.000 claims description 2
- 208000018937 joint inflammation Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000008127 lead poisoning Diseases 0.000 claims description 2
- 239000002457 oxidoreductase inhibitor Substances 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 208000008281 urolithiasis Diseases 0.000 claims description 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 150000001555 benzenes Chemical group 0.000 claims 2
- 230000001594 aberrant effect Effects 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 description 6
- 125000002993 cycloalkylene group Chemical group 0.000 description 5
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 3
- 229910005965 SO 2 Inorganic materials 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RHASGUGQMCVYMQ-UHFFFAOYSA-N N#Cc(cc1)ccc1-c1cnccc1SCC1(CC(O)=O)CC1 Chemical compound N#Cc(cc1)ccc1-c1cnccc1SCC1(CC(O)=O)CC1 RHASGUGQMCVYMQ-UHFFFAOYSA-N 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410398333.4A CN105439946B (zh) | 2014-08-13 | 2014-08-13 | 羧酸化合物及其制备方法和用途 |
| CN201410398333.4 | 2014-08-13 | ||
| PCT/CN2015/086605 WO2016023460A1 (zh) | 2014-08-13 | 2015-08-11 | 羧酸化合物及其制备方法和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524704A JP2017524704A (ja) | 2017-08-31 |
| JP2017524704A5 true JP2017524704A5 (cg-RX-API-DMAC7.html) | 2018-09-13 |
| JP6568929B2 JP6568929B2 (ja) | 2019-08-28 |
Family
ID=55303876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504421A Active JP6568929B2 (ja) | 2014-08-13 | 2015-08-11 | カルボン酸化合物、その製造方法および使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9809580B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3181557B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6568929B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102474640B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105439946B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015303597B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2956045C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2942259T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL250524B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ729037A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016023460A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105439946B (zh) * | 2014-08-13 | 2018-02-02 | 益方生物科技（上海）有限公司 | 羧酸化合物及其制备方法和用途 |
| JP6898330B2 (ja) * | 2015-12-28 | 2021-07-07 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | インドリジン誘導体、組成物、及び使用方法 |
| CN105884807A (zh) * | 2016-04-26 | 2016-08-24 | 昆药集团股份有限公司 | 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法 |
| CN106748987B (zh) * | 2016-11-18 | 2019-05-31 | 昆药集团股份有限公司 | 2-((3-(4-氰基萘-1-基)吡啶-4-基)硫基)-2-甲基丙酸钠盐的晶型 |
| TW201922706A (zh) * | 2017-10-04 | 2019-06-16 | 日商日本煙草產業股份有限公司 | 含氮雜芳基化合物及該化合物之醫藥用途 |
| CN108069940B (zh) * | 2017-12-20 | 2021-04-30 | 广东赛烽医药科技有限公司 | 硫代乙酸化合物、组合物及其应用 |
| CN108084153A (zh) * | 2017-12-20 | 2018-05-29 | 广东赛烽医药科技有限公司 | 吡啶基硫代乙酸化合物、组合物及其应用 |
| CN108440397B (zh) * | 2018-03-06 | 2020-06-05 | 南方医科大学 | 3-(萘-1-甲基取代)吡啶衍生物及其合成方法和应用 |
| WO2019183835A1 (en) | 2018-03-28 | 2019-10-03 | Inventisbio Shanghai Ltd. | Novel salt forms of urat-1 inhibitors |
| CN108484494B (zh) * | 2018-06-15 | 2021-07-30 | 沈阳药科大学 | 2-氧代-1,2-二氢吡啶-4-甲酸类化合物 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN113493407B (zh) * | 2020-04-03 | 2025-01-28 | 中国医学科学院药物研究所 | 一种吡啶类化合物及其制法和药物用途 |
| AR124985A1 (es) * | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| KR20230165774A (ko) * | 2021-03-01 | 2023-12-05 | 오리온 코포레이션 | 4h-피란-4-온 구조의 cyp11a1 억제제의 고체 형태 |
| CN113979931B (zh) * | 2021-10-08 | 2023-06-13 | 南方医科大学 | 一种吡啶3-胺衍生物及其制备方法和应用 |
| EP4516781A1 (en) * | 2022-04-27 | 2025-03-05 | Atom Therapeutics Co., Ltd. | Compound for reducing uric acid |
| WO2025060752A1 (zh) * | 2023-09-19 | 2025-03-27 | 湘北威尔曼制药股份有限公司 | 一种硫醚衍生物及其制备方法和应用 |
| WO2025060786A1 (zh) * | 2023-09-19 | 2025-03-27 | 湘北威尔曼制药股份有限公司 | 一种六元并五元稠环衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19541146A1 (de) * | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| FR2903984B1 (fr) * | 2006-07-24 | 2008-10-03 | Genfit Sa | Derives d'imidazolones substitues, preparation et utilisations |
| TW201109339A (en) * | 2009-08-28 | 2011-03-16 | Daiichi Sankyo Co Ltd | 3-(biaryloxy) propionic acid derivative |
| AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| WO2011159840A2 (en) * | 2010-06-16 | 2011-12-22 | Ardea Biosciences, Inc. | Phenylthioacetate compounds, compositions and methods of use |
| CN104023723B (zh) * | 2011-11-03 | 2017-05-31 | 阿迪亚生命科学公司 | 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物 |
| EP2800740A1 (en) * | 2012-01-04 | 2014-11-12 | Pfizer Limited | N-aminosulfonyl benzamides |
| WO2013158422A1 (en) * | 2012-04-17 | 2013-10-24 | E. I. Du Pont De Nemours And Company | Heterocyclic compounds for controlling invertebrate pests |
| CN105439946B (zh) * | 2014-08-13 | 2018-02-02 | 益方生物科技（上海）有限公司 | 羧酸化合物及其制备方法和用途 |
-
2014
- 2014-08-13 CN CN201410398333.4A patent/CN105439946B/zh active Active
-
2015
- 2015-08-11 NZ NZ729037A patent/NZ729037A/en unknown
- 2015-08-11 AU AU2015303597A patent/AU2015303597B2/en active Active
- 2015-08-11 ES ES15831615T patent/ES2942259T3/es active Active
- 2015-08-11 JP JP2017504421A patent/JP6568929B2/ja active Active
- 2015-08-11 EP EP15831615.8A patent/EP3181557B1/en active Active
- 2015-08-11 WO PCT/CN2015/086605 patent/WO2016023460A1/zh not_active Ceased
- 2015-08-11 CN CN201580043042.6A patent/CN106573908B/zh active Active
- 2015-08-11 KR KR1020177006929A patent/KR102474640B1/ko active Active
- 2015-08-11 CA CA2956045A patent/CA2956045C/en active Active
- 2015-08-11 US US15/501,387 patent/US9809580B2/en active Active
-
2017
- 2017-02-09 IL IL250524A patent/IL250524B/en active IP Right Grant
- 2017-10-03 US US15/723,785 patent/US9856239B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524704A5 (cg-RX-API-DMAC7.html) | ||
| JP2012527475A5 (cg-RX-API-DMAC7.html) | ||
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| ES2689484T3 (es) | Compuestos terapéuticos | |
| MX2020007532A (es) | Inhibidores de sarcomero cardiaco. | |
| JP2016518437A5 (cg-RX-API-DMAC7.html) | ||
| JP2018535967A5 (cg-RX-API-DMAC7.html) | ||
| RU2013119129A (ru) | Органические соединения | |
| WO2010059239A3 (en) | Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2014532726A5 (cg-RX-API-DMAC7.html) | ||
| JP2016528276A (ja) | プラーク退縮を促進するための組成物及び治療法 | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| RU2011143741A (ru) | Производное индолизина и его применение в медицинских целях | |
| JP2016512202A5 (cg-RX-API-DMAC7.html) | ||
| JP2017523219A5 (cg-RX-API-DMAC7.html) | ||
| JP2013528650A5 (cg-RX-API-DMAC7.html) | ||
| RU2003136077A (ru) | Применение соединений, обладающих совместной ингибирующей активностью в отношении nep (нейтральная эндопептидаза) и мр (металлопротеаза), для приготовления лекарственных средств | |
| RU2012134510A (ru) | Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников | |
| JP2012526769A5 (cg-RX-API-DMAC7.html) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JPWO2023195529A5 (cg-RX-API-DMAC7.html) | ||
| MX2024002409A (es) | Terapias contra el cancer. | |
| JP2021042207A (ja) | トロンボキサン受容体アンタゴニスト | |
| JP2019065009A5 (cg-RX-API-DMAC7.html) |